Alpuente A, et al. - Among 221 patients with chronic migraine (CM) at 6 and 12 months of follow-up, researchers identified clinical predictors of an excellent response to OnabotulinumtoxinA. A cohort study of individuals patients in a specialized Headache Clinic in treatment with OnabotulinumtoxinA were classified based on their improvement in frequency: no-response (< 25%) and excellent response (≥ 75%). The authors discovered a statistically significant mean decline in frequency and analgesic intake after 6 and also 12 months. Daily-frequency patients and MO show short-term clinical improvement. Patients with comorbidities that begin treatment earlier in the course of the disease require a longer treatment duration. The response profile to OnabotulinumtoxinA treatment specifies the minimum duration of treatment and the timepoint for a meaningful response. Excellent responders at 6 and 12 months showed a higher rate of improvement in pain intensity.